170 results about "Metered-dose inhaler" patented technology

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Aerosol formulations suitable for use in pressurised metered dose inhalers comprise a hydrofluoroalkane propellant, an medicament for inhalation and a surfactant which is a a C₈–C₁₆ fatty acid or salt thereof, a bile salt, a phospholipid, or an alkyl saccharide.

An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. The composition is stabilized by using a small amount of mineral acid and a suitable can having part or all of its internal metallic surfaces made of stainless steel, anodized aluminium or lined with an inert organic coating.

A dose counter for a metered dose inhaler includes a force sensor, an electronic controller, a memory for storing data indicative of a remaining number of doses and an electronic display device coupled to the controller for displaying the remaining number of doses. The dose counter is attached or integrated into a base of a canister containing medicament such that force applied to the base of the canister is registered by the force sensor, the controller being configured to measure force applied to the dose counter when depressing the canister and being responsive to measured force to decrement the remaining number of doses stored in the memory and shown on the display device.

A metered dose inhaler for use with a removable pressurized aerosol canister, or reservoir, having a display for indicating to a user the state of the canister. A memory device on the canister or a housing which houses the canister stores information indicative of doses dispensed from, or remaining in, the canister. That information is processed to provide and display information representative of the state of the canister.

A medicament dispenser including a medicament container having a dispensing outlet; an agitator for agitating the contents; and a driver for driving the agitator independent of any container movement. The medicament container may be a metered dose inhaler or delivering a suitable inhalable medicament.

Provided herein is a system that includes a metered dose inhaler device for pulmonary delivering to a subject at least one pre-determined vaporized amount of at least one pharmacologically active agent being in a plant material, wherein vaporization is effected by controllably heating the plant material so as to vaporize a pre-determined vaporized amount of the agent; the system further includes a controller in communication with the inhaler device, configured to control the pre-determined vaporized amount based on data indicative of at least one pharmacodynamic effect induced by the agent in the subject.

A collapsible inhalation device for use with a metered dose inhaler (MDI) dispenser includes an outlet end member, an inlet end member and a tubular, pliable, collapsible sleeve member attached at either end to the inlet and outlet members. The outlet end member includes a mouthpiece. The inlet end member includes an inlet port and an MDI dispenser mount structure configured to receive and engage the MDI dispenser. The inhalation device is positionable in each of an open position, wherein the sleeve member defines a chamber, and a closed position, wherein the sleeve member is collapsed and enveloped by the outlet end member and the inlet end member. When the inhalation device is in the open position with the MDI dispenser mounted in the MDI dispenser mount structure, a dose of the medication can be dispensed from the MDI dispenser into the chamber through the inlet port to mix with air in the chamber and thereby form a mixture of the air and the dose of the medication that can be inhaled by a patient from the chamber through the mouthpiece.

A metered dose inhaler is provided which includes a canister fitted in an actuator body. A metered dose of medication is delivered by compressing the canister in the actuator body. The metered dose inhaler includes an actuator that either fully (automatic) or partially (user-assisted) actuates the metered dose inhaler in order to deliver medication to the user.

The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a PDEIV inhibitor that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent comprising a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said anti-cholinergic agent component be tiotropium bromide.

A medication inhaler is provided for delivery of a medication to a patient from a canister having a valve stem, such as a MDI canister. The medication inhaler includes a chamber body having a fresh air inlet and a hollow spacer chamber. The inhaler further includes a canister retainer configured to move the canister between operational and stored positions, and an actuation lever for actuation of the valve stem to deliver a medication fluid into the hollow spacer chamber. In one example, the hollow spacer chamber tapers. In addition or alternatively, the chamber body includes a nozzle having an outlet, and a fresh air inlet having an outlet proximate the outlet of the nozzle. In addition or alternatively, the medication inhaler includes a canister adapter for accommodation of various size canisters. In addition or alternatively, the chamber body includes an inlet portion having a geometry for guiding the valve stem.

A pressurized metered dose dispenser (100) for dispensing an aerosol formulation comprising particles of a medicament suspended in liquefied propellant, optionally in combination with one or more excipients, the dispenser comprising an aerosol container (1) equipped with a metered dose valve (10), where a formulation chamber is defined in part by the internal walls of the container, and wherein the dispenser further comprises a porous, fluid permeable, particulate semi-permeable body (40) located within the formulation chamber adjacent to the metered dose valve.

The invention provides a pMDI metering valve comprising at least one component which comprises a desiccant-entrained material, a pMDI closed container system containing a desiccant-entrained material, and a method of stabilising the fine particle mass (FPM) of an inhalation drug formulation emitted by a pMDI closed container system comprising providing a desiccant-entrained material inside the pMDI closed container system so as to be in contact with the formulation therein.

Nanoparticles are prepared from a colloidal system comprising a continuous phase and micelles, the micelles comprising surfactant material. A microemulsion is formed by admixing the colloidal system with a solution of an active material, such as a medicament, dissolved in a solvent wherein the solution forms a disperse phase with the micelles of surfactant material. At least the dispersed phase is quenched to a solid state and the continuous phase and solvent are removed to produce the nanoparticles. The nanoparticles can be incorporated in an aerosol composition suitable for deep lung delivery by means of a metered dose inhaler.

Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.

A metered-dose inhaler includes at least one vessel and an actuator for receiving the at least one vessel. The at least one vessel includes a first reservoir containing a first formulation and a second reservoir containing a second formulation. The metered-dose inhaler is actuable when the at least one vessel is received by the actuator. The metered-dose inhaler is configured to simultaneously deliver a first metered dose of the first formulation and a second metered dose of the second formulation upon actuation.

A flexible bag aerosol holding chamber is sealed around the outlet passage of the actuator for a pressurized metered-dose inhaler. An elastic-loaded mouthpiece is sealed around the inlet passage of the actuator so that the user may intermittently break the seal around the inlet passage by withdrawing the mouthpiece, thus allowing inhalation of a portion of the aerosol contents of the chamber. In a preferred embodiment the invention the aerosol contains a compound which has traditionally been smoked such as nicotine or a cannabinoid, The user may draw upon the chamber's contents a number of times at a frequency analogous to smoking until the chamber is fully collapsed. One inhaler actuation, and one filled chamber, are comparable to one cigarette. The collapsible bag chamber allows for economy of inhaler actuations relative to user inhalations, without the aerosol being diluted by ambient air.